We investigated whether CRP derived from PVAT promotes neointimal hyperplasia after vascular injury, as well as the underlying molecular mechanism, with the goal of providing evidence for the potential of CRP as a novel target for preventing vascular restenosis after angioplasty in cardiovascular high-risk patient with obesity and diabetes. Here, CRP is linked to obesity due to melanocortin 4 receptor deficiency.